Answers are grounded in this paper and cite their sources.
One reagent for two techniques: Compound [111In]1 provides a platform for sequential radionuclide and optical imaging of prostate cancer through targeting of the prostate-specific membrane antigen. Because the same subject can be dual-imaged after one injection of the agent, these findings support rapid clinical translation.
No takes yet. Share an insight, caveat, or question.
Banerjee et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: